psalexa

Psoriasis Drugs Market Research Report: By Type (Biologic Drugs, Small-Molecule Systemic Drugs, Topical Therapies), Mechanism of Action (Tumor Necrosis Factor-Alpha Inhibitors, Phosphodiesterase Type 4 Inhibitors, Interleukin Inhibitors), Route of Administration (Oral, Parenteral, Topical) - Global Industry Analysis and Demand Forecast to 2030

  • Published: March 2021
  • Report Code: LS12172
  • Available Format: PDF
  • Pages: 250

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Analysis Period

1.4 Market Data Reporting Unit

1.4.1 Value

1.5 Market Size Breakdown by Segment

1.5.1 Market Segmentation by Type

1.5.2 Market Segmentation by Mechanism of Action (MoA)

1.5.3 Market Segmentation by Route of Administration (RoA)

1.5.4 Market Segmentation by Region

1.6 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.1.1 Paid

2.1.2 Unpaid

2.1.3 P&S Intelligence Database

2.2 Primary Research

2.2.1 Breakdown of Primary Research, by Region

2.2.2 Breakdown of Primary Research, by Industry Participant

2.2.3 Breakdown of Primary Research, by Company Type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Currency Conversion Rates

2.6 Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

5.1 Dermatology Drugs Market – The Parent Market

Chapter 6. Definition of Market Segments

6.1 By Type

6.1.1 Biologic Drugs

6.1.2 Small-Molecule Systemic Drugs

6.1.3 Topical Therapies

6.2 By MoA

6.2.1 TNF-Alpha Inhibitors

6.2.2 PDE4 Inhibitors

6.2.3 Interleukin Inhibitors

6.2.4 Others

6.3 By RoA

6.3.1 Oral

6.3.2 Parenteral

6.3.3 Topical

Chapter 7. Industry Outlook

7.1 Market Dynamics

7.1.1 Trends

7.1.1.1 Increasing number of product approvals

7.1.2 Drivers

7.1.2.1 Rising geriatric population

7.1.2.2 Increasing prevalence of psoriasis

7.1.2.3 Growing awareness about psoriasis

7.1.2.4 Extensive pipeline of psoriasis drugs

7.1.2.5 Impact analysis of drivers on market forecast

7.1.3 Restraints

7.1.3.1 Patent expiry of some popular drugs

7.1.3.2 Side-effects of certain classes of therapeutic drugs

7.1.3.3 Impact analysis of restraints on market forecast

7.1.4 Opportunities

7.1.4.1 Huge potential in emerging markets

7.2 Impact of COVID-19

7.2.1 Porter’s Five Forces Analysis

Chapter 8. Global Market Size and Forecast

8.1 Overview

8.2 Market Revenue, by Type (2015–2030)

8.3 Market Revenue, by MoA (2015–2030)

8.4 Market Revenue, by RoA (2015–2030)

8.5 Market Revenue, by Region (2015–2030)

Chapter 9. North America Market Size and Forecast

9.1 Overview

9.2 Market Revenue, by Type (2015–2030)

9.3 Market Revenue, by MoA (2015–2030)

9.4 Market Revenue, by RoA (2015–2030)

9.5 Market Revenue, by Country (2015–2030)

Chapter 10. Europe Market Size and Forecast

10.1 Overview

10.2 Market Revenue, by Type (2015–2030)

10.3 Market Revenue, by MoA (2015–2030)

10.4 Market Revenue, by RoA (2015–2030)

10.5 Market Revenue, by Country (2015–2030)

Chapter 11. APAC Market Size and Forecast

11.1 Overview

11.2 Market Revenue, by Type (2015–2030)

11.3 Market Revenue, by MoA (2015–2030)

11.4 Market Revenue, by RoA (2015–2030)

11.5 Market Revenue, by Country (2015–2030)

Chapter 12. LATAM Market Size and Forecast

12.1 Overview

12.2 Market Revenue, by Type (2015–2030)

12.3 Market Revenue, by MoA (2015–2030)

12.4 Market Revenue, by RoA (2015–2030)

12.5 Market Revenue, by Country (2015–2030)

Chapter 13. MEA Market Size and Forecast

13.1 Overview

13.2 Market Revenue, by Type (2015–2030)

13.3 Market Revenue, by MoA (2015–2030)

13.4 Market Revenue, by RoA (2015–2030)

13.5 Market Revenue, by Country (2015–2030)

Chapter 14. U.S. Market Size and Forecast

14.1 Overview

14.2 Market Revenue, by Type (2015–2030)

14.3 Market Revenue, by MoA (2015–2030)

14.4 Market Revenue, by RoA (2015–2030)

Chapter 15. Canada Market Size and Forecast

15.1 Overview

15.2 Market Revenue, by Type (2015–2030)

15.3 Market Revenue, by MoA (2015–2030)

15.4 Market Revenue, by RoA (2015–2030)

Chapter 16. Germany Market Size and Forecast

16.1 Overview

16.2 Market Revenue, by Type (2015–2030)

16.3 Market Revenue, by MoA (2015–2030)

16.4 Market Revenue, by RoA (2015–2030)

Chapter 17. France Market Size and Forecast

17.1 Overview

17.2 Market Revenue, by Type (2015–2030)

17.3 Market Revenue, by MoA (2015–2030)

17.4 Market Revenue, by RoA (2015–2030)

Chapter 18. U.K. Market Size and Forecast

18.1 Overview

18.2 Market Revenue, by Type (2015–2030)

18.3 Market Revenue, by MoA (2015–2030)

18.4 Market Revenue, by RoA (2015–2030)

Chapter 19. Italy Market Size and Forecast

19.1 Overview

19.2 Market Revenue, by Type (2015–2030)

19.3 Market Revenue, by MoA (2015–2030)

19.4 Market Revenue, by RoA (2015–2030)

Chapter 20. Spain Market Size and Forecast

20.1 Overview

20.2 Market Revenue, by Type (2015–2030)

20.3 Market Revenue, by MoA (2015–2030)

20.4 Market Revenue, by RoA (2015–2030)

Chapter 21. Japan Market Size and Forecast

21.1 Overview

21.2 Market Revenue, by Type (2015–2030)

21.3 Market Revenue, by MoA (2015–2030)

21.4 Market Revenue, by RoA (2015–2030)

Chapter 22. China Market Size and Forecast

22.1 Overview

22.2 Market Revenue, by Type (2015–2030)

22.3 Market Revenue, by MoA (2015–2030)

22.4 Market Revenue, by RoA (2015–2030)

Chapter 23. India Market Size and Forecast

23.1 Overview

23.2 Market Revenue, by Type (2015–2030)

23.3 Market Revenue, by MoA (2015–2030)

23.4 Market Revenue, by RoA (2015–2030)

Chapter 24. Australia Market Size and Forecast

24.1 Overview

24.2 Market Revenue, by Type (2015–2030)

24.3 Market Revenue, by MoA (2015–2030)

24.4 Market Revenue, by RoA (2015–2030)

Chapter 25. South Korea Market Size and Forecast

25.1 Overview

25.2 Market Revenue, by Type (2015–2030)

25.3 Market Revenue, by MoA (2015–2030)

25.4 Market Revenue, by RoA (2015–2030)

Chapter 26. Brazil Market Size and Forecast

26.1 Overview

26.2 Market Revenue, by Type (2015–2030)

26.3 Market Revenue, by MoA (2015–2030)

26.4 Market Revenue, by RoA (2015–2030)

Chapter 27. Mexico Market Size and Forecast

27.1 Overview

27.2 Market Revenue, by Type (2015–2030)

27.3 Market Revenue, by MoA (2015–2030)

27.4 Market Revenue, by RoA (2015–2030)

Chapter 28. Saudi Arabia Market Size and Forecast

28.1 Overview

28.2 Market Revenue, by Type (2015–2030)

28.3 Market Revenue, by MoA (2015–2030)

28.4 Market Revenue, by RoA (2015–2030)

Chapter 29. South Africa Market Size and Forecast

29.1 Overview

29.2 Market Revenue, by Type (2015–2030)

29.3 Market Revenue, by MoA (2015–2030)

29.4 Market Revenue, by RoA (2015–2030)

Chapter 30. Competitive Landscape

30.1 List of Major Drugs and Their Manufacturers

30.2 Recent Strategic Developments of Key Players

30.2.1 Product Launches and Approvals

30.2.2 Acquisitions

30.2.3 Other Developments

Chapter 31. Company Profiles

31.1 Novartis AG

31.1.1 Business Overview

31.1.2 Product and Service Offerings

31.1.3 Key Financial Summary

31.2 Pfizer Inc.

31.2.1 Business Overview

31.2.2 Product and Service Offerings

31.2.3 Key Financial Summary

31.3 Bristol-Myers Squibb Company

31.3.1 Business Overview

31.3.2 Product and Service Offerings

31.3.3 Key Financial Summary

31.4 Johnson & Johnson

31.4.1 Business Overview

31.4.2 Product and Service Offerings

31.4.3 Key Financial Summary

31.5 Merck & Co. Inc.

31.5.1 Business Overview

31.5.2 Product and Service Offerings

31.5.3 Key Financial Summary

31.6 AbbVie Inc.

31.6.1 Business Overview

31.6.2 Product and Service Offerings

31.6.3 Key Financial Summary

31.7 Eli Lilly and Company

31.7.1 Business Overview

31.7.2 Product and Service Offerings

31.7.3 Key Financial Summary

31.8 GlaxoSmithKline plc

31.8.1 Business Overview

31.8.2 Product and Service Offerings

31.8.3 Key Financial Summary

31.9 Mylan N.V.

31.9.1 Business Overview

31.9.2 Product and Service Offerings

31.9.3 Key Financial Summary

31.10 Bausch Health Companies Inc.

31.10.1 Business Overview

31.10.2 Product and Service Offerings

31.10.3 Key Financial Summary

31.11 Amgen Inc.

31.11.1 Business Overview

31.11.2 Product and Service Offerings

31.11.3 Key Financial Summary

31.12 Galderma S.A.

31.12.1 Business Overview

31.12.2 Product and Service Offerings

31.13 LEO Pharma A/S

31.13.1 Business Overview

31.13.2 Product and Service Offerings

31.13.3 Key Financial Summary

Chapter 32. Appendix

32.1 Abbreviations

32.2 Sources and References

32.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 LIST OF MAJOR PIPELINE DRUGS FOR PSORIASIS

TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 PATENT EXPIRATION OF PSORIASIS DRUGS

TABLE 5 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 6 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 7 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 8 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 9 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 10 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 11 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 12 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY REGION, $M (2015–2020)

TABLE 13 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY REGION, $M (2021–2030)

TABLE 14 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 15 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 16 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 17 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 18 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 19 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 20 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2020)

TABLE 21 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 22 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 23 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 24 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 25 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 26 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 27 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 28 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2020)

TABLE 29 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 30 APAC PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 31 APAC PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 32 APAC PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 33 APAC PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 34 APAC PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 35 APAC PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 36 APAC PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2020)

TABLE 37 APAC PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 38 LATAM PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 39 LATAM PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 40 LATAM PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 41 LATAM PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 42 LATAM PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 43 LATAM PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 44 LATAM PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2020)

TABLE 45 LATAM PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 46 MEA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 47 MEA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 48 MEA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 49 MEA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 50 MEA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 51 MEA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 52 MEA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2020)

TABLE 53 MEA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 54 U.S. PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 55 U.S. PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 56 U.S. PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 57 U.S. PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 58 U.S. PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 59 U.S. PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 60 CANADA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 61 CANADA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 62 CANADA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 63 CANADA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 64 CANADA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 65 CANADA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 66 GERMANY PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 67 GERMANY PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 68 GERMANY PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 69 GERMANY PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 70 GERMANY PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 71 GERMANY PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 72 FRANCE PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 73 FRANCE PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 74 FRANCE PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 75 FRANCE PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 76 FRANCE PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 77 FRANCE PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 78 U.K. PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 79 U.K. PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 80 U.K. PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 81 U.K. PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 82 U.K. PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 83 U.K. PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 84 ITALY PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 85 ITALY PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 86 ITALY PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 87 ITALY PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 88 ITALY PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 89 ITALY PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 90 SPAIN PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 91 SPAIN PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 92 SPAIN PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 93 SPAIN PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 94 SPAIN PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 95 SPAIN PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 96 JAPAN PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 97 JAPAN PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 98 JAPAN PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 99 JAPAN PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 100 JAPAN PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 101 JAPAN PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 102 CHINA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 103 CHINA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 104 CHINA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 105 CHINA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 106 CHINA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 107 CHINA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 108 INDIA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 109 INDIA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 110 INDIA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 111 INDIA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 112 INDIA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 113 INDIA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 114 AUSTRALIA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 115 AUSTRALIA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 116 AUSTRALIA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 117 AUSTRALIA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 118 AUSTRALIA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 119 AUSTRALIA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 120 SOUTH KOREA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 121 SOUTH KOREA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 122 SOUTH KOREA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 123 SOUTH KOREA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 124 SOUTH KOREA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 125 SOUTH KOREA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 126 BRAZIL PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 127 BRAZIL PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 128 BRAZIL PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 129 BRAZIL PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 130 BRAZIL PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 131 BRAZIL PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 132 MEXICO PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 133 MEXICO PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 134 MEXICO PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 135 MEXICO PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 136 MEXICO PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 137 MEXICO PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 138 SAUDI ARABIA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 139 SAUDI ARABIA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 140 SAUDI ARABIA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 141 SAUDI ARABIA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 142 SAUDI ARABIA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 143 SAUDI ARABIA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 144 SOUTH AFRICA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2020)

TABLE 145 SOUTH AFRICA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 146 SOUTH AFRICA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2020)

TABLE 147 SOUTH AFRICA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 148 SOUTH AFRICA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2020)

TABLE 149 SOUTH AFRICA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 150 LIST OF MAJOR DRUGS AND THEIR MANUFACTURERS

TABLE 151 NOVARTIS AG – AT A GLANCE

TABLE 152 NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 153 PFIZER INC. – AT A GLANCE

TABLE 154 PFIZER INC. – KEY FINANCIAL SUMMARY

TABLE 155 BRISTOL-MYERS SQUIBB COMPANY – AT A GLANCE

TABLE 156 BRISTOL-MYERS SQUIBB COMPANY – KEY FINANCIAL SUMMARY

TABLE 157 JOHNSON & JOHNSON – AT A GLANCE

TABLE 158 JOHNSON & JOHNSON – KEY FINANCIAL SUMMARY

TABLE 159 MERCK & CO. INC. – AT A GLANCE

TABLE 160 MERCK & CO. INC. – KEY FINANCIAL SUMMARY

TABLE 161 ABBVIE INC. – AT A GLANCE

TABLE 162 ABBVIE INC. – KEY FINANCIAL SUMMARY

TABLE 163 ELI LILLY AND COMPANY – AT A GLANCE

TABLE 164 ELI LILLY AND COMPANY – KEY FINANCIAL SUMMARY

TABLE 165 GLAXOSMITHKLINE PLC – AT A GLANCE

TABLE 166 GLAXOSMITHKLINE PLC – KEY FINANCIAL SUMMARY

TABLE 167 MYLAN N.V. – AT A GLANCE

TABLE 168 MYLAN N.V. – KEY FINANCIAL SUMMARY

TABLE 169 BAUSCH HEALTH COMPANIES INC. – AT A GLANCE

TABLE 170 BAUSCH HEALTH COMPANIES INC. – KEY FINANCIAL SUMMARY

TABLE 171 AMGEN INC. – AT A GLANCE

TABLE 172 AMGEN INC. – KEY FINANCIAL SUMMARY

TABLE 173 GALDERMA S.A. – AT A GLANCE

TABLE 174 LEO PHARMA A/S – AT A GLANCE

TABLE 175 LEO PHARMA A/S – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

 

FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 CURRENCY CONVERSION RATES FOR USD (2020)

FIG 8 GLOBAL PSORIASIS DRUGS MARKET SUMMARY

FIG 9 VOICE OF INDUSTRY EXPERTS/KOLS

FIG 10 BARGAINING POWER OF BUYERS

FIG 11 BARGAINING POWER OF SUPPLIERS

FIG 12 INTENSITY OF RIVALRY

FIG 13 THREAT OF NEW ENTRANTS

FIG 14 THREAT OF SUBSTITUTES

FIG 15 GLOBAL PSORIASIS DRUGS MARKET SNAPSHOT

FIG 16 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 17 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 18 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 19 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY REGION, $M (2015–2030)

FIG 20 NORTH AMERICA PSORIASIS DRUGS MARKET SNAPSHOT

FIG 21 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 22 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 23 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 24 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2030)

FIG 25 EUROPE PSORIASIS DRUGS MARKET SNAPSHOT

FIG 26 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 27 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 28 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 29 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2030)

FIG 30 APAC PSORIASIS DRUGS MARKET SNAPSHOT

FIG 31 APAC PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 32 APAC PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 33 APAC PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 34 APAC PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2030)

FIG 35 LATAM PSORIASIS DRUGS MARKET SNAPSHOT

FIG 36 LATAM PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 37 LATAM PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 38 LATAM PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 39 LATAM PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2030)

FIG 40 MEA PSORIASIS DRUGS MARKET SNAPSHOT

FIG 41 MEA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 42 MEA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 43 MEA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 44 MEA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2015–2030)

FIG 45 U.S. PSORIASIS DRUGS MARKET SNAPSHOT

FIG 46 U.S. PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 47 U.S. PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 48 U.S. PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 49 CANADA PSORIASIS DRUGS MARKET SNAPSHOT

FIG 50 CANADA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 51 CANADA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 52 CANADA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 53 GERMANY PSORIASIS DRUGS MARKET SNAPSHOT

FIG 54 GERMANY PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 55 GERMANY PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 56 GERMANY PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 57 FRANCE PSORIASIS DRUGS MARKET SNAPSHOT

FIG 58 FRANCE PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 59 FRANCE PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 60 FRANCE PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 61 U.K. PSORIASIS DRUGS MARKET SNAPSHOT

FIG 62 U.K. PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 63 U.K. PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 64 U.K. PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 65 ITALY PSORIASIS DRUGS MARKET SNAPSHOT

FIG 66 ITALY PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 67 ITALY PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 68 ITALY PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 69 SPAIN PSORIASIS DRUGS MARKET SNAPSHOT

FIG 70 SPAIN PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 71 SPAIN PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 72 SPAIN PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 73 JAPAN PSORIASIS DRUGS MARKET SNAPSHOT

FIG 74 JAPAN PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 75 JAPAN PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 76 JAPAN PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 77 CHINA PSORIASIS DRUGS MARKET SNAPSHOT

FIG 78 CHINA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 79 CHINA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 80 CHINA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 81 INDIA PSORIASIS DRUGS MARKET SNAPSHOT

FIG 82 INDIA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 83 INDIA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 84 INDIA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 85 AUSTRALIA PSORIASIS DRUGS MARKET SNAPSHOT

FIG 86 AUSTRALIA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 87 AUSTRALIA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 88 AUSTRALIA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 89 SOUTH KOREA PSORIASIS DRUGS MARKET SNAPSHOT

FIG 90 SOUTH KOREA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 91 SOUTH KOREA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 92 SOUTH KOREA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 93 BRAZIL PSORIASIS DRUGS MARKET SNAPSHOT

FIG 94 BRAZIL PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 95 BRAZIL PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 96 BRAZIL PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 97 MEXICO PSORIASIS DRUGS MARKET SNAPSHOT

FIG 98 MEXICO PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 99 MEXICO PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 100 MEXICO PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 101 SAUDI ARABIA PSORIASIS DRUGS MARKET SNAPSHOT

FIG 102 SAUDI ARABIA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 103 SAUDI ARABIA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 104 SAUDI ARABIA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 105 SOUTH AFRICA PSORIASIS DRUGS MARKET SNAPSHOT

FIG 106 SOUTH AFRICA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2015–2030)

FIG 107 SOUTH AFRICA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2015–2030)

FIG 108 SOUTH AFRICA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2015–2030)

FIG 109 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)

FIG 110 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)

FIG 111 BRISTOL-MYERS SQUIBB COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)

FIG 112 JOHNSON & JOHNSON – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)

FIG 113 MERCK & CO. INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)

FIG 114 ABBVIE INC. – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2020)

FIG 115 ELI LILLY AND COMPANY – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2020)

FIG 116 GLAXOSMITHKLINE PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)

FIG 117 MYLAN N.V. – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2019)

FIG 118 BAUSCH HEALTH COMPANIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)

FIG 119 AMGEN INC. – REVENUE SPLIT BY PRODUCT AND GEOGRAPHY (2020)

FIG 120 LEO PHARMA A/S – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2020)

Place An Order
USD 4900 USD 6400 USD 8400
Customized Report Solution

Get a bespoke market intelligence solution

 
We are committed to ensuring the highest level of client satisfaction
Quality Acknowledgement
Quality Acknowledgement

Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you

Unmatched Standards
Unmatched Standards

Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights

Reach Us
Reach Us Whenever You Need Us

With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required

Data Security
Complete Data Security

We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws